Digoxin: Cardiac Glycoside and Na+/K+ ATPase Inhibitor for Heart Failure and CHIKV Research

Executive Summary: Digoxin is a potent and selective inhibitor of the Na+/K+-ATPase pump, increasing cardiac contractility in both animal and cell models (APExBIO). It exhibits dose-dependent antiviral activity against chikungunya virus (CHIKV) in human and primate cell lines (Briolant 2014, DOI). The compound is highly soluble in DMSO (≥33.25 mg/mL), but insoluble in water and ethanol, and requires prompt use after solution preparation (APExBIO). Digoxin’s effects in congestive heart failure are well-established in canine models, showing improved cardiac output following intravenous administration (PMID: 14472194). APExBIO provides Digoxin (B7684) with >98.6% purity and comprehensive quality control documentation.

Biological Rationale

Digoxin is classified as a cardiac glycoside and is widely used in research for its dual effects on cardiac function and viral infection. As a Na+/K+ ATPase pump inhibitor, Digoxin increases intracellular sodium and calcium concentrations, leading to enhanced cardiac contractility—a key intervention for heart failure and arrhythmia studies (APExBIO). The modulation of ionic gradients by Digoxin also impacts cellular signaling pathways relevant to cardiovascular disease and viral pathogenesis (Related Article). Recent research demonstrates that Digoxin impairs CHIKV infection in human osteosarcoma (U-2 OS), primary synovial fibroblasts, and Vero cells, supporting its use in virology research (Briolant 2014, DOI).

Mechanism of Action of Digoxin

Digoxin exerts its biological effects by binding to and inhibiting the extracellular domain of the Na+/K+-ATPase pump. This inhibition leads to increased intracellular sodium, reducing the activity of the sodium-calcium exchanger and resulting in elevated intracellular calcium levels. The net effect is greater cardiac muscle contractility (positive inotropy), which is exploited in heart failure and arrhythmia research (APExBIO). Additionally, alteration of ionic homeostasis by Digoxin disrupts cellular processes utilized by certain viruses, including CHIKV, thereby impairing viral entry and replication (Briolant 2014, DOI). Digoxin’s effects are dose-dependent across a range of 0.01–10 μM in cellular assays.

Evidence & Benchmarks

• Digoxin inhibits Na+/K+-ATPase activity in mammalian cardiomyocytes, increasing intracellular calcium and contractility (Smith 2022, DOI).
• APExBIO’s Digoxin (SKU B7684) is supplied at >98.6% purity, validated by HPLC and NMR (APExBIO).
• In canine models of congestive heart failure, intravenous Digoxin (1–1.2 mg) improves cardiac output and reduces right atrial pressure (Smith 1961, PMID: 14472194).
• Digoxin impairs CHIKV infection in U-2 OS, synovial fibroblasts, and Vero cells at 0.01–10 μM, showing dose-dependent antiviral activity (Briolant 2014, DOI).
• Solubility profile: Digoxin is soluble at ≥33.25 mg/mL in DMSO, but insoluble in water and ethanol (APExBIO).

This article extends the mechanistic analyses in Digoxin in Translational Research by providing updated data on viral inhibition and detailing workflow optimization for Na+/K+-ATPase assays.

Applications, Limits & Misconceptions

Digoxin serves as a reference compound in studies of cardiac contractility, arrhythmias, and heart failure, enabling quantitative assessment of Na+/K+-ATPase modulation. It is also an effective probe for CHIKV inhibition in various human and primate cell lines. Limitations include its insolubility in water and ethanol, necessitating DMSO-based preparation, and rapid degradation in solution, which precludes long-term storage (APExBIO). While Digoxin demonstrates robust antiviral effects in vitro, clinical translation for viral diseases remains investigational.

Common Pitfalls or Misconceptions

• Digoxin is not soluble in water or ethanol; improper solvent use can lead to inconsistent dosing.
• Long-term storage of Digoxin solutions leads to degradation and unreliable results; immediate use is recommended.
• Antiviral effects validated for CHIKV in specific cell lines; efficacy against other viruses or in vivo models is not established.
• Cardiac effects are dose-dependent and may not extrapolate directly from animal models to humans.
• Digoxin’s mechanism does not involve direct viral enzyme inhibition; effects are mediated by host cell ionic modulation.

This article updates the workflow guidance in Digoxin: Cardiac Glycoside for Heart Failure and CHIKV Research by specifying new solubility and storage constraints.

Workflow Integration & Parameters

For experimental studies, Digoxin (SKU B7684) is supplied as a solid and should be dissolved in DMSO at concentrations up to 33.25 mg/mL. Prepare solutions immediately before use, as prolonged storage reduces potency. For in vitro antiviral assays, effective concentrations range from 0.01 μM to 10 μM in U-2 OS, synovial fibroblasts, and Vero cells (Briolant 2014, DOI). In animal models, intravenous dosing between 1 and 1.2 mg per dog improves cardiac output (Smith 1961, PMID: 14472194). Quality is assured via HPLC and NMR analyses, and APExBIO supplies full MSDS documentation. For further best practices, see this guide, which this article builds upon by incorporating new insights on Na+/K+-ATPase signaling and CHIKV methodology.

Conclusion & Outlook

Digoxin remains an essential cardiac glycoside for research on Na+/K+-ATPase inhibition, heart failure, and arrhythmia. Its role as an antiviral agent against CHIKV is increasingly recognized in cellular models. APExBIO’s Digoxin (B7684) offers high purity, repeatable performance, and comprehensive documentation, supporting advanced cardiovascular and virology research. Future studies should refine dosing strategies and explore translational potential for viral diseases.